CD300A

Across TCGA pan-cancer cohorts, CD300A RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of CD300A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD300A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD300A is over-expressed in tumor, although a few such as LUSC and LIHC show the opposite, repressed pattern.

KIRC, KIRP, and HNSC are the cancer types where CD300A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD300A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+2.973	<.001	12	view →
KIRP	Male	All	+1.798	<.001	11	view →
HNSC	All	All	+0.747	<.001	11	view →
THCA	All	II,III,IV	+0.757	<.001	8	view →
STAD	All	II,III,IV	+1.132	<.001	7	view →
LUSC	All	II,III,IV	−1.016	<.001	6	view →
LIHC	Male	All	−0.967	<.001	3	view →
PAAD	All	All	−1.424	.048	2	view →
ESCA	All	All	+1.415	.011	2	view →
COAD	Female	III,IV	−0.836	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

CD300A–KIRC

Open the KIRC breakdown →